PCH
JSPR icon

Polar Capital Holdings’s Jasper Therapeutics JSPR Stock Holding History

Polar Capital Holdings’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-581,538
Closed -$10.9M – 313
2024
Q3 		$10.9M Hold
581,538
– – 0.05% 195
2024
Q2 		$13.2M Buy
+581,538
New +$13.9M 0.08% 165

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Polar Capital Holdings's JSPR Position: Q4 2024 in Review

Polar Capital Holdings sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 581,538 shares — an estimated $10.9M sold.

Polar Capital Holdings first reported a position in JSPR in Q2 2024 and held it in 2 quarters. The position peaked at $13.2M in Q2 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

  • Polar Capital Holdings reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Polar Capital Holdings sold 581,538 Jasper Therapeutics shares in Q4 2024, an estimated $10.9M.
  • Polar Capital Holdings first reported a position in Jasper Therapeutics in Q2 2024 and held it in 2 quarters.
  • Polar Capital Holdings's Jasper Therapeutics position peaked at $13.2M in Q2 2024.
  • 87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on Polar Capital Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.